Laboratorios Rubió and CIMASciences will attend the Liver Meeting 2022 (AASLD), which will be held from the 4th to the 8th of November. This is one of the leading international platforms for the pharmaceutical sector regarding healthcare for liver diseases.
The AASLD is one of the great windows for the industry for new trends and innovation, as it is a showcase for cutting-edge science, attendance of expert speakers who are the top minds in hepatology, and a peer networking event for meeting your future best partners.
Our company will be at booth #840. Likewise, the booth will have an exclusive area for clients and guests where the protagonist will be our OWLiver®.
Laboratorios Rubió and Cima Sciences are launching in the US the OWLiver®, in a new commitment to fight NAFLD and improve the patient’s quality of life. Recently, it is registered with code CPT-PLA 0344U.
The OWLiver® test is a non-invasive diagnostic method, which is based on a blood test to determine through metabolomics that is a panel of biomarkers. The OWLiver medical software algorithm panel generates a report reflecting a complete characterization of metabolites reflecting the amount of liver fat, inflammation, and fiber deposition. This allows to reliably diagnose the patient in all the harmful phases of metabolic liver disease.
